New Products
Barclays Wealth Launches New Structured Products

Barclays Wealth is launching a new range of protected investments and continuing its Emerging Markets Optimiser: the firm says it is seeing record demand for its growth, income and recovery products.
Open between 10 November 2008 and 9 January 2009, the new suite includes the Regular Income Bond, which links to the Dow Jones Stoxx50 index of European "supersector" stocks. The five-year RIB offers a fixed annual income of 7.75 per cent or a quarterly income of 1.9 per cent. Investors’ full capital is returned at maturity unless the index has fallen by more than 40 per cent at any time during the term and is at a lower level than its starting level by the maturity date, in which case capital is reduced on a 1:1 basis.
For investors seeking a recovery vehicle the range also includes the Super Tracker, a three- or five-year investment which provides geared exposure to the FTSE 100. The three-year option will return 2.5 times the rise in the index up to a maximum 50 per cent return while the five-year option offers four times the rise up to a maximum 100 per cent return. Investors’ full capital will be repaid at maturity unless the FTSE 100 falls by more than 50 per cent at any time during the term and is at a lower level than its starting level by the maturity date, in which case capital is lost 1:1 with the index.
For investors seeking full capital protection the new suite offers three further choices.
The Emerging Markets Optimiser is a five-year investment offering exposure to 23 emerging markets around the globe. Uniquely, the EMO offers daily adjusted exposure to the iShares MSCI Emerging Markets Index Fund, which gives exposure to the BRIC economies and key developing markets including South Korea, Taiwan and South Africa. Broadly, EMO’s dynamic exposure strategy lowers exposure to the fund when its performance is volatile, and increases exposure when its volatility is less pronounced.
All of these products can be sold before their maturity but the investor will not receive the benefits promised at maturity and might get back less than was invested.